Edition:
United States

BioTime Inc (BTX.A)

BTX.A on American Stock Exchange

3.27USD
12:44pm EDT
Change (% chg)

$-0.03 (-0.91%)
Prev Close
$3.30
Open
$3.35
Day's High
$3.35
Day's Low
$3.27
Volume
11,699
Avg. Vol
70,608
52-wk High
$4.00
52-wk Low
$2.26

BTX.A

Chart for BTX.A

About

BioTime, Inc. is a clinical-stage biotechnology company. The Company is focused on the field of regenerative medicine, specifically pluripotent stem cell technology. The Company is engaged in the research and development of therapeutic products for oncology, orthopedics, retinal and neurological diseases and disorders, blood and... (more)

Overall

Beta: 1.96
Market Cap(Mil.): $365.82
Shares Outstanding(Mil.): 110.85
Dividend: --
Yield (%): --

Financials

  BTX.A Industry Sector
P/E (TTM): 10.15 49.14 30.32
EPS (TTM): 0.33 -- --
ROI: 24.22 -2.23 13.10
ROE: 46.36 5.00 14.24

BRIEF-Biotime qtrly loss per share $0.05

* Biotime, Inc. Reports fourth quarter and fiscal year 2016 financial results and recent corporate accomplishments

Mar 16 2017

BRIEF-Biotime expands OpRegen clinical trial in dry-AMD with opening of first US sites

* BioTime expands opregen® clinical trial in dry-amd with opening of first us sites

Mar 13 2017

BRIEF-BioTime reports pro forma gain on deconsolidation of OncoCyte subsidiary

* BioTime - Deconsolidation of Oncocyte's financial's from co's consolidated financial statements; co to report pro forma non-cash gain of about $56 million

Feb 21 2017

BRIEF-Biotime announces closing of public offering

* Biotime Inc announces closing of public offering of common stock Source text for Eikon: Further company coverage:

Feb 15 2017

BRIEF-BioTime announces pricing of public offering of common stock

* Says public offering of 6.48 million common shares priced at $2.70 per share Source text for Eikon: Further company coverage:

Feb 10 2017

BRIEF-Biotime announces proposed public offering of common stock

* Biotime, Inc. announces proposed public offering of common stock Source text for Eikon: Further company coverage:

Feb 09 2017

BRIEF-BioTime appoints Stephana Patton as general counsel

* BioTime appoints industry veteran, Stephana Patton, Ph.D., J.D., as general counsel Source text for Eikon: Further company coverage:

Feb 07 2017

BRIEF-BioTime's OpRegen presents first patient cohort data from clinical trial

* First patient cohort data from biotime's OpRegen clinical trial in dry-AMD to be presented at ISOPT Clinical Symposium on december 2, 2016

Oct 20 2016

More From Around the Web

Competitors

  Price Chg
Sanofi SA (SASY.PA) €84.24 -0.27
Baxter International Inc (BAX.N) $51.98 0.00
Hospira, Inc. (HSP.N) -- --

Earnings vs. Estimates